The basics are simple: strength, liquid volume, concentration and target amount. Choose the tool that matches what you actually have in front of you.
Arithmetic only — not a dose recommendation.
These tools convert numbers you already know. They do not choose a target amount. For pens, you must also confirm the exact device type and click/dose-selector system; for vials, confirm concentration and syringe type before converting between mg, mL and syringe units.
Important if you are using a pen
Do not guess the device, click scale or technique from appearance. Watch the pen guide and confirm the exact device before using click calculations.
Choose your format
What the numbers mean
Vial label
10 mg
total peptide
mg = amount of peptide
Look on the vial label for the total amount, for example 10 mg.
2 mL
liquid added
mL = liquid volume
mL describes liquid. It is not the same thing as mg.
100 units = 1 mL
Units = syringe volume marks
On a U-100 syringe, the unit scale is another way of measuring liquid volume.
1 mg
equals
1,000 mcg
mg and mcg are both amounts
mcg is simply a smaller unit. The calculator converts between them.
Core formula
Concentration = total peptide ÷ liquid volume
Example: 50 mg in 2.5 mL = 20 mg/mL. If a target amount is selected, volume = target amount ÷ concentration. On a U-100 syringe, 1 mL corresponds to 100 units.
Simple calculator
4. Result
—
Does body size change the amount?
Some approved medicines use fixed amounts. Others explicitly use body weight, such as mg/kg, or body-surface area, which can use both height and weight. Height by itself is not a general dosing rule.
The Pep Report therefore never scales a target amount automatically from body size. If a study, prescribing label or qualified clinician uses a weight- or BSA-based method, start with that known amount and use our calculator only for the arithmetic conversion.
Reference cards
These cards put The Pep Report’s research reference amounts and schedules in one place. They are educational references rather than individualized recommendations. Open a peptide to see the evidence, formulation context and detailed dosing notes behind the number.
Reference
100–300 mcg (3–9 clicks)
2–3× daily on an empty stomach · 8–12 weeks on, 4 weeks off
Reference
1 mg/day (days 1–15), then 2 mg/day
Daily, before bed
Reference
2.5 mg per injection
Daily wk 1–4, 5×/week wk 5–8, 2–3×/week wk 9–12 · 4 weeks off
Reference
1.6–4.8 mg per injection
Daily initially, then 5×/week, then 2–3×/week in the cited 12-week protocol · 12 weeks
Reference
200–500 mcg daily
Daily · 4–8 weeks
Reference
50–75 mcg to start, building to 250–500 mcg
Once weekly maintenance · UV exposure after injecting
Reference
5–15 mg per week, split into 2–3 injections
2–3× weekly · 2–4 weeks on, 2–4 weeks off
Reference
25 mg to start, +25 mg every 3 days
3× weekly
Reference
1.75 mg as needed
As needed · On-demand
Reference
0.5 mg weekly, stepping up by 0.5 mg every 2 weeks to 3 mg
Weekly · 12-week titration, then evaluate
Reference
250–500 mcg
1–2× daily · 2–8 weeks on
Reference
300–1,000 mcg
1–3× daily · 2–4 weeks on, 1–2 weeks off
Reference
5–10 mg daily
Daily · 8–12 weeks
Reference
1,000–2,000 mcg (16–32 clicks)
Once daily, 5 days/week · 2–3 months on, 1 month off
Reference
500 mcg
Daily, morning · 8 weeks on, 8 weeks off
Reference
250–500 mcg daily
Daily · 4–6 weeks
Reference
1–2.5 mg
2–3× weekly · 4–6 weeks
Reference
0.25 mg weekly start; maintenance 0.5–2.4 mg weekly, up to 7.2 mg for certain adults
Once-weekly injection; approved oral formulations are taken once daily
Suggested protocols
Starting amounts, step-ups, frequency and cycle lengths for the compounds below. Pair each protocol with the calculator above to turn a target amount into a real draw or click count for your vial or pen.
UV exposure should always come after injecting.
View the Melanotan II profile →| Weeks | Weekly dose | What to expect |
|---|---|---|
| 1–2 | 0.5 mg | Minimal effects. Mild appetite decrease possible. GI calm. |
| 3–4 | 1 mg | First noticeable food noise reduction. Possible mild nausea. |
| 5–6 | 1.5 mg | Clear satiety signal. Nausea is common: slow eating, small portions. |
| 7–8 | 2 mg | Meaningful caloric deficit starting to compound. |
| 9–10 | 2.5 mg | Strong GLP-1 + glucagon effect. Fatigue on injection day possible. |
| 11–12 | 3 mg | Evaluate here. Many people stay at their current dose for months. |
Cycle
8 weeks on, 8 weeks off.
Cycle
Off cycle of 4 weeks afterwards.
Cycle
2–4 weeks on, followed by 2–4 weeks off.
Cycle
8–12 weeks on, 4 weeks off.
Cycle
2–3 months on, 1 month off.
Cycle
2–8 weeks on.
Cycle
2–4 weeks on, 1–2 weeks off.